Among 212 heart failure patients, those with low vitamin C intake were 2.4 times more likely to show elevated hsCRP, and those with both low intake and hsCRP above 3 mg/L were about twice as likely to die of cardiovascular disease during the first year of follow-up.
Section archive
Heart Failure
- All desks
- Abortion
- Accutane
- Acetaminophen
- Acid Reflux
- Acidic Foods
- Acne
- Acrylamide
- Acupuncture
- Additives
- ADHD
- Adiposity
- Advisories
- Aerobic Exercise
- Aflatoxin
- Agave
- Agent Orange
- Aging
- Agriculture
- AIDS
- Air Pollution
- Airline Passengers
- Airport
- ALA
- Alcohol
- Alcoholic Beverage
- Alerts
- Allergy
- Alli
- Aloe Vera
- ALS
- Alternative Medicine
- Aluminum
- Alzheimer's
- Amalgam
- AMD
- Ampyra
- Amygdala
- Anal Cancer
- And
- Anemia
- Angiogenesis
- Animal Protein
- Animals
- Anorexia
- Anthocyanins
- Anthrax
- Anti-Angiogenesis
- Anti-Obesity
- Antibacterial
- Antibiotic
Vitamins
Vitamin C, Omega 3 fatty acids cut death risk from cardiovascular disease
Following 58,730 Japanese adults for 16.5 years, researchers found women with the highest vitamin C intake were 30% less likely to die of stroke and 37% less likely to die of coronary heart disease. The association was not significant in men, and vitamins A and E showed none.
Drug
20% patients not qualified for Implantable cardioverter-defibrillators
Of more than 100,000 ICD recipients in a national registry, 22.5% got the device for a non-evidence-based indication, a JAMA study found. Those patients died in hospital three times as often as the rest, 0.57% versus 0.18%, and had a higher complication rate after the procedure.
Drug
FDA okays three defibrillators to treat heart failure
FDA approved three Boston Scientific cardiac resynchronization defibrillators for heart failure patients with left bundle branch block. In a three-year trial of 1,820 patients, those with the block had 57 percent lower risk of death and heart failure than with a defibrillator alone.
Drug
Diabetes drug linked to increased risk of heart failure
A cohort study of 40,000 Canadian diabetes patients aged 66 and older found significantly lower rates of heart failure and death with pioglitazone than rosiglitazone, though heart attack rates were similar. The authors stop short of calling pioglitazone safer.
5 stories